DIABECELL®

uses pig islets to replace human islets that have been destroyed by type 1 diabetes.

Advancing a cure for type 1 diabetes

At Diatranz Otsuka Limited (DOL), we are using the incredible biological similarities between humans and other mammals to develop cellular therapies which can improve the lives of people living with serious disease. Using animal cells and tissues in this way is known as Xenotransplantation, or Xeno for short.  

 

Our vision is to become the world leader in Xenotransplantation. With DIABECELL®, our lead product for type I diabetes, in late stages of clinical development we are well on our way to achieving that goal.

 

Our ownership of a unique breed of pigs from the remote Auckland Islands of New Zealand gives us our "Power to Xeno". This, combined with access to Living Cell Technologies'  proprietary cell-encapsulation technology IMMUPELTM provides the technology foundation for DOL to develop a breakthrough therapeutic option for a debilitating disease.

 

DOL is a privately held New Zealand incorporated company, formed in 2011 as a joint-venture between Living Cell Technologies and Otsuka Pharmaceutical Factory.

— 3 October 2016

Data from the Argentine (DIA09) Clinical Trial published

Two articles relating to DIABECELL and the Argentine DIA09 clinical study have been published titled "Clinical Benefit of Islet Xenotransplantation for the Treatment of Type 1 Diabetes" and "No PERV transmission during a clinical trial of pig islet cell transplantation".

Read More Read Less

— 25 August 2016

Update on Southland pig facility

Diatranz Otsuka Limited (DOL) is currently undertaking a consultation process which proposes closing the Southland pig facility.

 

While we are working through the employment process with the 5 full-time and 2 part-time employees, no final decision has been made.

 

Further development of DIABECELL will take place in the United States.

 

Should the decision be made to close the facility we will work with Southern Heirloom Breeds Trust to rehome the 33 pigs.

Read More Read Less
Load More
Sector news

— 3 October 2016

Data from the Argentine (DIA09) Clinical Trial published

Two articles relating to DIABECELL and the Argentine DIA09 clinical study have been published titled "Clinical Benefit of Islet Xenotransplantation for the Treatment of Type 1 Diabetes" and "No PERV transmission during a clinical trial of pig islet cell transplantation".

Read More Read Less

— 25 August 2016

Update on Southland pig facility

Diatranz Otsuka Limited (DOL) is currently undertaking a consultation process which proposes closing the Southland pig facility.

 

While we are working through the employment process with the 5 full-time and 2 part-time employees, no final decision has been made.

 

Further development of DIABECELL will take place in the United States.

 

Should the decision be made to close the facility we will work with Southern Heirloom Breeds Trust to rehome the 33 pigs.

Read More Read Less
Load More